Ortho RTi receives European patent allowance

iStock-115809714_LRG.jpg

Ortho Regenerative Technologies (CSE:ORTH) received a notice of allowance from the European Patent Office for a patent entitled, "Soluble Physiological Chitosan Formulations Combined with Platelet-Rich Plasma (PRP) for Tissue Repair."  

Once the administrative process is complete, the patent will provide intellectual property protection for the formulation of the company’s Ortho-R for the biologic repair of tissue.

  "This allowance adds to the formidable intellectual property estate that we are building to cover our game-changing propriety biopolymer platform around the globe," Dr. Brent Norton, executive chairman and CEO, said in a statement.

"We believe that Ortho-R holds great promise for improving the repair of soft tissue injuries, including rotator cuff tears, the meniscus in knees and articular cartilage,” he added.

Sydney Stewart